WO1989009622A1 - Anticorps chimeriques specifiques au recepteur il-2 - Google Patents

Anticorps chimeriques specifiques au recepteur il-2 Download PDF

Info

Publication number
WO1989009622A1
WO1989009622A1 PCT/US1989/001578 US8901578W WO8909622A1 WO 1989009622 A1 WO1989009622 A1 WO 1989009622A1 US 8901578 W US8901578 W US 8901578W WO 8909622 A1 WO8909622 A1 WO 8909622A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
sequence
segment
antibody
mouse
Prior art date
Application number
PCT/US1989/001578
Other languages
English (en)
Inventor
Cary L. Queen
Original Assignee
Protein Design Labs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs, Inc. filed Critical Protein Design Labs, Inc.
Priority to KR1019890702368A priority Critical patent/KR900700134A/ko
Publication of WO1989009622A1 publication Critical patent/WO1989009622A1/fr
Priority to FI895955A priority patent/FI895955A0/fi
Priority to NO89895022A priority patent/NO895022L/no
Priority to DK631689A priority patent/DK631689A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention relates generally to the combination of recombinant DNA and monoclonal antibody technologies for developing novel therapeutic and other agents and, more particularly, to the production of chimeric antibodies specific for the human interleukin-2 receptor and the use of such chimeric antibodies in treating T-cell mediated human disorders.
  • the immune response is mediated by two types of cells that interact specifically with foreign material, i.e. , antigens.
  • B-cells are responsible for the production of antibodies.
  • T-cells include a wide variety of cellular subsets controlling the in vivo function of both B-cells and a wide variety of other hematopoietic cells, including T- cells.
  • IL-2 interleukin-2
  • T-cell growth factor T-cell growth factor 2
  • IL-2 interacts with a specific high-affinity membrane receptor (Greene, . , et al., Progress in Hematology XIV, E. Brown, ed. , Grune and Statton, New York (1986), at pgs. 283 ff) .
  • the human IL-2 receptor is a complex glycoprotein, with one chain 55kD in size (Leonard, . et al., J. Biol. Che . 260;1872 (1985)).
  • a gene encoding this protein has been isolated, and predicts a 272 a ino acid peptide, including a 21 amino acid signal peptide, (see, Leonard, . et al., Nature 311: 626 (1984)).
  • IL-2 receptors can be detected on T-cells, but also on cells of the onocyte-macrophage family, Kupffer cells of the liver, Langerhans 1 cells of the skin and, of course, activated T-cells.
  • resting T-cells, B-cells or circulating machrophages typically do not display the IL-2 receptor (Herrmann, et al., J. Exp. Med. 162:1111 (1985)).
  • the anti-Tac monoclonal antibody has also been used to define lymphocyte functions that require IL-2 interaction, and has been shown to inhibit various T-cell functions, including the generation of cytotoxic and suppressor T lymphocytes in cell culture. Also, based on studies with anti-Tac, a variety of disorders are now associated with improper IL-2 receptor expression by T-cells, in particular adult T-cell leukemia.
  • the IL-2 receptor has been shown to be an ideal target for novel therapeutic approaches to T-cell mediated diseases.
  • the anti-Tac monoclonal antibody can be used either alone or as an immunoconjugate (e.g. with Ricin A, isotopes and the like) to effectively remove cells bearing the IL-2 receptor.
  • These agents can, for example, theoretically eliminate IL-2 receptor-expressing leukemic cells, certain B-cells, or activated T-cells involved in a disease state, yet allow the retention of mature normal T- cells and their precursors to ensure the capability of mounting a normal T-cell immune response as needed.
  • other T-cell specific agents can destroy essentially all peripheral T-cells, which limits therapeutic efficacy.
  • the use of monoclonal antibodies specific for the IL-2 receptor can be expected to have therapeutic utility in autoimmune diseases, organ transplantation and any unwanted response by activated T-cells. Indeed, clinical trials have been initiated (see, generally, Waldman, T., Science 232:727- 732 (1986) , which is incorporated herein by reference) .
  • the use of the anti-Tac monoclonal antibody has certain drawbacks, particularly in repeated therapeutic regimens. As a mouse monoclonal, it does not fix human complement well, whereas a human equivalent may be more efficient. More importantly, however, anti-Tac monoclonal antibody contains substantial urine amino acid sequences that will be antigenic when injected into a human patient.
  • the present invention provides novel compositions useful in the treatment of T-cell mediated human disorders, the compositions containing a chimeric antibody specifically capable of binding to human IL-2 receptors, such as at the epitope bound by the anti-Tac monoclonal antibody.
  • the IL-2 chimeric antibody can have two pairs of light chain/heavy chain complexes, wherein at least one pair has chains comprising mouse variable regions joined with human constant region segments, with or without naturally-associated J and D segments.
  • the chimeric antibodies, or binding fragments thereof, of the present invention may be produced by a variety of recombinant DNA techniques, with ultimate expression in transfected cells, preferably immortalized eukaryotic cells, such as myeloma or hybridoma cells.
  • Polynucleotides comprising a first sequence coding for a human immunoglobulin constant region and a second sequence coding for the desired mouse immunoglobulin variable or hypervariable region can be produced synthetically or by combining appropriate cDNA and genomic DNA segments.
  • the compounds When the chimeric antibodies are complexed with a cytotoxic agent, such as a radionuclide, a ribosomal inhibiting protein or a cytotoxic agent active at cell surfaces, the compounds will be particularly useful in treating T-cell mediated disorders.
  • a cytotoxic agent such as a radionuclide, a ribosomal inhibiting protein or a cytotoxic agent active at cell surfaces
  • these compounds can be provided in a pharmaceutically accepted dosage form, which will vary depending on the mode of administration.
  • Figure 1 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac light chain.
  • Figure 2 depicts the DNA coding sequence and putative amino acid sequence of the V and J regions of the anti-Tac heavy chain.
  • Figures 3-10 are schematic diagrams of the plasmids utilized to demonstrate the present invention.
  • Figure 11 represents an overview of a preferred strategy for preparation of V and J regions for insertion into plasmids.
  • DNA sequences encoding mouse variable/human constant region chimeric antibodies capable of binding epitopes on human IL-2 receptors are provided.
  • large quantities of chimeric antibodies can be produced.
  • the chimeric antibodies will have substantially the same binding profile or characteristics as (e.g. , be cross-reactive or capable of blocking) the binding of the anti-Tac monoclonal antibody, such as antibodies produced by the myeloma cell line deposited with the A.T.C.C. and designated accession number CRL 9688.
  • These chimeric antibodies find use, for example, in the treatment of T-cell mediated disorders in human patients.
  • the basic immunoglobin structural unit is known to comprise a tetramer.
  • Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25kD) and one "heavy" chain (about 50-70kD) .
  • the NH -terminus of each chain begins a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the COOH terminus of each chain defines a constant region primarily responsible for effector function.
  • Light chains are classified as either kappa or lambda.
  • Heavy chains are classified (and subclassified) as gamma, mu, alpha, delta, or epsilon, and define the immunoglobulin's isotype as IgG, IgM, IgA, IgD and IgE, respectively.
  • the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 12 more amino acids.
  • Chimeric antibodies are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin gene segments belonging to different species.
  • the variable (V) segments of the genes for a mouse monoclonal antibody may be joined to human constant (C) segments, such as 7 , and 7 .
  • a preferred therapeutic chimeric antibody is thus a hybrid protein consisting of the V or antigen-binding domain from a mouse antibody and the C or effector domain from a human antibody, although other mammalian species may be used.
  • Human chimeric antibodies have at least three potential advantages over mouse antibodies for use in human therapy: 1) Because the effector portion is human, it may interact better with the other parts of the human immune system (e.g. , destroy the target cells more efficiently by complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC) ) .
  • CDC complement-dependent cytotoxicity
  • ADCC antibody-dependent cellular cytotoxicity
  • the human immune system should not recognize the C region of the chimeric antibody as foreign, and therefore the antibody response against an injected chimeric antibody should be less than against a totally foreign mouse antibody.
  • Injected mouse antibodies have been reported to have a half-life in the human circulation much shorter than the half-life of normal antibodies (Shaw, D. et al., J. Immunol. 138:4534-4538 (1987)) . It is possible that injected chimeric antibodies will have a half-life more like that of human antibodies, allowing smaller and less frequent doses to be given.
  • the present invention is directed to recombinant DNA segments encoding the heavy and/or light chain variable or hypervariable regions from the anti-Tac monoclonal antibody.
  • the DNA segments encoding these regions will typically be joined to DNA segments encoding appropriate constant regions, such as human gamma heavy chain regions or human kappa light chain regions.
  • appropriate constant regions such as human gamma heavy chain regions or human kappa light chain regions.
  • the preferred variable region DNA sequences which on expression code for the polypeptide chains comprising the anti-Tac light and heavy chain variable regions (with naturally-associated J regions) , are shown in Figures 1 and 2, respectively. Due to codon degeneracy and non-critical amino-acid substitutions, other DNA sequences can be readily substituted for those sequences, as detailed below.
  • the DNA segments will typically further include an expression control DNA sequence operably linked to the chimeric antibody coding sequences, including naturally- associated or heterologous promoter regions.
  • the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the light chains, heavy chains, light/heavy chain dimers or intact chimeric antibodies may follow.
  • variable and constant regions are subject to substantial natural modification, yet are “substantially identical” and still capable of retaining their respective activities.
  • Human constant region DNA sequences can be isolated in accordance with well known procedures from a variety of human cells, but preferably immortalized B-cells. Suitable source cells for the DNA sequences and host cells for expression and secretion can be obtained from a number of sources, such as the American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," Fifth edition (1985) Rockville, Maryland, U.S.A., which is incorporated herein by reference).
  • substantially identical modified heavy and light chains can be readily designed and manufactured utilizing various recombinant DNA techniques well known to those skilled in the art.
  • the chains can vary from the naturally-occurring sequence at the primary structure level by several amino acid substitutions, terminal and intermediate additions and deletions, and the like.
  • polypeptide fragments comprising only a portion (usually at least about 60-80%, typically 90-95%) of the primary structure may be produced, which fragments possess one or more immunoglobulin activities (e.g.. complement fixation activity) , while exhibiting lower immunogenicity.
  • the immunoglobulin-related genes contain separate functional regions, each having one or more distinct biological activities. These may be fused to functional regions from other genes (e.g. r enzymes, see, commonly assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is incorporated herein by reference) to produce fusion proteins (e.g.. immunotoxins) having novel properties.
  • r enzymes see, commonly assigned U.S.S.N. 132,387, filed Dec. 15, 1987, which is incorporated herein by reference
  • modifications of the genes may be readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see. Gillman and Smith, Gene 8.:81-97 (1979) ; Roberts, S. et al. Nature 328:731-734 (1987); and U.S. Patent no.
  • Preferred DNA segments encoding variable regions of the present invention will typically be substantially homologous to the sequences of Figures 1 and 2 (i.e., capable of hybridizing to the sequences under stringent conditions of low salt and high temperature) , most preferrably at least about 90-95% homologous or more.
  • nucleic acid sequences of the present invention capable of ultimately expressing the desired chimeric antibodies can be formed from a variety of different polynucleotides (genomic or cDNA, RNA, etc.) and components (e.g. , V, J, D, and C regions) , as well as by a variety of different techniques. Joining appropriate genomic sequences is presently the most common method of production, but cDNA sequences may also be utilized (see, European Patent Application Nos. 85102655.8, 85305604.2, 84302368.0 and 85115311.4, as well as PCT Application Nos. GB85/00392 and US86/02269, all of which are incorporated herein by reference) .
  • the DNA sequences of the present invention will be expressed in hosts after the sequences have been operably linked to (i.e. , positioned to ensure the functioning of) an expression control sequence.
  • These expression vectors are typically replicable in the host organisms either as episomes or as an integral part of the host chromosomal DNA.
  • expression vectors will contain selection markers, e.g. , tetracycline or neomycin, to permit detection of those cells transformed with the desired DNA sequences (see, e.g. , U.S. Patent 4,704,362, which is incorporated herein by reference) .
  • E. coli is one prokaryotic host useful particularly for cloning the DNA sequences of the present invention.
  • microbial hosts suitable for use include bacilli, such as Bacillus subtilus, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species.
  • prokaryotic hosts one can also make expression vectors, which will typically contain expression control sequences compatible with the host cell (e.g. , an origin of replication) .
  • expression control sequences compatible with the host cell (e.g. , an origin of replication) .
  • any number of a variety of well- known promoters will be present, such as the lactose promoter system, a tryptophan (trp) promoter system, a beta-lactamase promoter system, or a promoter system from phage lambda.
  • the promoters will typically control expression, optionally with an operator sequence, and have ribosome binding site sequences and the like, for initiating and completing transcription and translation.
  • Saccharomvces is a preferred host, with suitable vectors having expression control sequences, such as promoters, including 3-phosphoglycerate kinase or other glycolytic enzymes, and an origin of replication, termination sequences and the like as desired.
  • mammalian tissue cell culture may also be used to produce the polypeptides of the present invention (see, Winnacker, "From Genes to Clones,” VCH Publishers, N.Y., N.Y. (1987), which is incorporated herein by reference) .
  • Eukaryotic cells are actually preferred, because a number of suitable host cell lines capable of secreting intact immunoglobulins have been developed in the art, and include the CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, etc, but preferably transformed B-cells or hybrido as.
  • Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter, an enhancer (Queen, C.
  • Preferred expression control sequences are promoters derived from immunoglobulin genes, SV40, Adenovirus, Bovine Papilloma Virus, and the like.
  • the vectors containing the DNA segments of interest can be transferred into the host cell by well-known methods, which vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, whereas calcium phosphate treatment may be used for other cellular hosts. (See generally, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, (1982), which is incorporated herein by reference.)
  • the whole chimeric antibodies, their dimers, or individual light and heavy chains of the present invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, fraction column chro atography, gel electrophoresis and the like. (See, generally. Scopes, R. , Protein Purification, Springer-Verlag, N.Y. (1982).) Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically or in developing and performing assay procedures, immunofluorescent stainings, and the like. (See, generally, Immunological Methods, Vols. I and II, Eds. Lefkovits and Pernis, Academic Press, New York, N.Y. (1979 and 1981).)
  • the chimeric antibodies of the present invention will typically find use individually in treating a T-cell mediated disease state. Generally, where the cell linked to a disease has been identified as IL-2 receptor bearing, then the chimeric antibodies are suitable (see, U.S.S.N. 7- 085,707, entitled “Treating Human Malignancies and Disorders,” which is incorporated herein by reference) .
  • Other diseases include Type I diabetes, multiple sclerosis, rheumatoid arthritis, Lupus erythematosus, and Myasthenia Gravis.
  • the antibodies of the present invention may also be used in combination with other antibodies, particularly human chimeric antibodies or human monoclonal antibodies reactive with other markers on cells responsible for the disease.
  • suitable T-cell markers can include those grouped into the so-called "Clusters of Differentia ion," as named by the First International Leukocyte Differentiation Workshop, Leukocyte Typing, Eds. Bernard, et al., Springer-Verlag, N.Y. (1984) , which is incorporated herein by reference.
  • the chimeric antibodies can also be used as separately administered compositions given in conjunction with chemotherapeutic or immunosuppressive agents.
  • the agents will include a cephalosporin or a purine analog (e.g. , methotrexate, 6-mercaptopurine, or the like) , but numerous additional agents (e.g.. cyclophospha ide, sulfa drugs, etc.) well-known to those skilled in the art may also be utilized.
  • a preferred pharmaceutical composition of the present invention comprises the use of the subject chimeric antibodies in immunotoxins.
  • I munotoxins are characterized by two components and are particularly useful for killing selected cells in vitro or in vivo.
  • One component is a cytotoxic agent which is usually fatal to a cell when attached or absorbed.
  • the second component known as the "delivery vehicle,” provides a means for delivering the toxic agent to a particular cell type, such as cells comprising a carcinoma.
  • the two components are commonly chemically bonded together by any of a variety of well-known chemical procedures.
  • the cytotoxic agent is a protein and the second component is an intact immunoglobulin, such as a chimeric antibody
  • the linkage may be by way of heterobifunctional cross-linkers, e.g..
  • Cytotoxic agents can include radionuclides, such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212; a number of chemotherapeutic drugs, such as vindesine, methotrexate, adriamycin, and cisplatinum; and cytotoxic proteins such as ribosomal inhibiting proteins, pokeweed antiviral protein, abrin and ricin (or their A- chains, diphtheria toxin A-chains, Pseudomonas exotoxin A, etc.) or an agent active at the cell surface, such as the phospholipase enzymes (e.g. , phospholipase C) .
  • radionuclides such as Iodine-131, Yttrium-90, Rhenium-188, and Bismuth-212
  • chemotherapeutic drugs such as vindesine, methotrexate, adriamycin, and cisp
  • the delivery component of the immunotoxin will include the chimeric antibodies of the present invention. Intact chimeric immunoglobulins or their binding fragments, such as Fab, F(ab 2 ) , etc., are preferably used. Typically, the chimeric antibodies in the immunotoxins will be of the human IgM or IgG isotype, but other mammalian constant regions may be utilized as desired.
  • compositions for parenteral administration are particularly - useful for parenteral administration, i.e. , subcutaneously, intramuscularly or intravenously.
  • the compositions for parenteral administration will commonly comprise a solution of the antibody or a cocktail thereof dissolved in an accept- able carrier, preferably an aqueous carrier.
  • aqueous carriers can be used, e.g. , water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
  • concentration of antibody in these formulations can vary widely, i.e.. from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 50 g of antibody.
  • a typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of antibody.
  • Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th Ed. , Mack Publishing Company, Easton, Pennsylvania (1980) , which is incorporated herein by reference.
  • the antibodies of this -invention can be ly ⁇ philized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g. , with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.
  • compositions containing the present human chimeric antibodies or a cocktail thereof can be administered for the prophylactic and/or therapeutic treatments.
  • compositions are administered to a patient already, in an amount sufficient to cure or at least partially arrest the infection and its complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per dose, with dosages of from 5 to 25 mg per patient being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is life-threatening or potentially life- threatening situations.
  • compositions containing the present antibodies or a cocktail thereof are administered to a patient not already in a disease state to enhance the patient's resistance.
  • Such an amount is defined to be a "prophylactically effective dose.”
  • the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per dose, especially 0.5 to 2.5 mg per patient.
  • Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician.
  • the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat the patient.
  • Chimeric antibodies of the present invention can further find a wide variety of utilities vitro.
  • the chimeric antibodies can be utilized for T-cell typing, for isolating specific IL-2 receptor bearing cells or fragments of the receptor, for vaccine preparation, or the like.
  • the chimeric antibodies may either be labeled or unlabeled.
  • Unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the chimeric antibody, such as antibodies specific for human immunoglobulin constant regions.
  • second antibodies labeled antibodies
  • the chimeric antibodies can be directly labeled.
  • labels may be employed, such as radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands
  • Kits can also be supplied for use with the subject antibodies in the protection against or detection of a cellular activity or for the presence of a selected antigen.
  • the subject antibody composition of the present invention may be provided, usually in a lyophilized form in a container, either alone or in conjunction with additional antibodies specific for the desired cell type.
  • the antibodies which may be conjugated to a label or toxin, or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g.
  • serum albumin or the like, and a set of instructions for use.
  • these materials will be present in less than about 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration.
  • a second antibody capable of binding to the chimeric antibody is employed in an assay, this will usually be present in a separate vial.
  • the second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.
  • a splice and polyadenylation signal from the animal virus SV40 (850 bp) .
  • e Another part of SV40 containing its origin of replication (700 bp) ;
  • f Part of the plasmid pBR322, extending from the Sph I site to the Eco Rl site of the plasmid pMLl (Lusky, M and Botchan, M. Nature 293:79-81: 2300 bp) including the Amp gene and origin of replication.
  • pKcatH was cut with Bgl II, and the ends filled in with Klenow polymerase.
  • An Xba I linker having the sequence GCTCTAGAGC, was inserted at the filled-in Bgl II site. The resulting plasmid is called pKcatH - Xba.
  • pKcatH - Xba was cut partially with Xho II, run on an agar ⁇ se gel, and full-length linear plasmid (i.e. , plasmid cut exactly once with Xho II) was isolated.
  • the DNA was cut with Bam HI, run on a gel and the 5600 bp fragment isolated. Because of its size, this fragment had to extend from the Bam site to the Xho II site at the end of the CAT gene (Fig. 3). The fragment was ligated by itself.
  • the resulting plasmid is called pKcatH - Xba - BX. It is similar to pKcatH but has an Xba I site in place of the Bgl II site and is missing the Xho II - Bam HI SV40 fragment (Fig. 4) .
  • the plasmid pSV2neo (Southern, P.J. and Berg, P. J. Mol. App. Genet. 1:327-341 (1982)), was cut with Eco RI and Bam HI, and the large Eco RI - Bam HI fragment ligated to the same Eco RI - Bam HI fragment from pKcatH - Xba - BX used in (4) .
  • the resulting plasmid is called pSV2neo - EH - K , which is like pSV2gpt - EH - K, but has the Neo gene in place of the Gpt gene.
  • pSV2gpt - E réelle - c was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
  • a fragment of the cloned human K constant segment gene (Hieter, P.A. et al., Cell 22:197-207 (1980)) was purified, extending from a Hind III site 336 bp before the coding region, to an Xba I site about 800 bp beyond the coding region, and the ends filled in.
  • the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second*fragment was joined to the Xba I site and the Xba I site of the second fragment to the Bam HI site.
  • pV ⁇ l Fig. 6
  • An Xba I fragment containing the VJ region of the cloned anti-Tac light chain gene was prepared by in vitro mutagenesis (see, below) .
  • pV ⁇ l was cut with Xba I, treated with phosphatase, and ligated with the Xba I fragment.
  • a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pLTAC2 (Fig. 7) .
  • pSV2neo - E réelle - K was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
  • a 2800 bp fragment containing the human C7I gene was purified from the phage HG3A (Ellison, J.W. et al., Nucleic Acids Res. 10:4071-4079 (1982)), extending from a Hind III site 210 bp before the CHI exon to a Pvu II site about 1100 bp after the CH3 exon, and the ends filled in.
  • the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second fragment was joined to the Xba I site and the Pvu II site of the second fragment to the Bam HI site. Because of the sequences of these sites, this recreated an Xba I site and a Bam HI site.
  • the new plasmid is called pV 7 lneo (Fig. 8) .
  • pSV2neo - E réelle - K was cut with Xba I and Bam HI and the ends filled in with Klenow polymerase.
  • a 3600 bp fragment containing the human C 7 3 gene (Takahashi, N. et al., Cell ⁇ 671-679 (1982)) was purified extending from a Hind III site 210 bp before the CHI exon to a Pvu II site about 1100 bp after the CH3 exon, and the ends filled in.
  • the two fragments were ligated together, and a plasmid selected in which the Hind III site of the second fragment was joined to the Xba I site and the Pvu II site of the second fragment to the Bam HI site.
  • the new plasmid is called pV 3neo and is identical to pV7lneo except it has the C 7 3 gene instead of C 7 I. 10.
  • An Xba I fragment containing the VJ region of the cloned anti-Tac heavy china gene was prepared by in vitro mutagenesis (see, below) .
  • pV7lneo was cut with Xba I, treated with phosphatase, and ligated with the Xba I fragment.
  • a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pHTAC.
  • PV7I Three additional plasmids were prepared respectively from pV7lneo, pV 3neo and pHTAC, called respectively PV7I, PV73 and pGTACl.
  • the original plasmid was cut with Hind III and Bam HI, and the large Hind III - Bam HI fragment purified.
  • the plasmid pXBohph containing the Hyg gene (Blochlinger, K. and Diggelmann, H. Mol. Cell. Biol. 4:2929-2931 (1984)) was cut with Hind III and Bam HI and a 1600 bp fragment containing the Hyg gene purified.
  • the fragments from the original plasmids were each ligated to the pXbohph fragment.
  • PV 7 I is shown in Fig. 9 and pGTACl in Fig.
  • pHTAC was cut with Xba I and the small Xba I fragment, containing the heavy VJ region, purified.
  • PV 3 was cut with Xba I, treated with phosphatase, and ligated with the small Xba I fragment.
  • a plasmid was selected in which the VJ region had the same orientation as the following C region, and called pGTAC3. It is similar to pGTACl, but has the C 7 3 region instead of the C7I region.
  • mRNA was extracted from approximately 10-8 ascites cells of the anti-Tac hybrido a by the guanidium isothiocyanate method followed with poly A selection on Hybond- AP paper (Amersham) .
  • cDNA was prepared by the method of Gubler and Hoffman (Gubler, U. and Hoffman, B.J. Gene
  • plaques Approximately 10,000 plaques were screened with the oligonucleotide probes. About 100 plaques were positive for the 7 probe and 40 for the 7 probe.
  • VJ segments of the other pair of K clones were sequences completely and were identical (Fig. 1) .
  • This light chain uses the JK5 segment and contains all the amino acid residues conserved in mouse K light chains (Kabat, E. A. et al.. Sequences of Proteins of Immunological Interest, particularly pg. 45 et seq, all of which is incorporated herein by reference) .
  • Plasmid vectors were prepared for the construction and expression of chimeric light and heavy chain genes as described above.
  • the plasmid pV ⁇ l (Fig. 6) contains the human K genomic C segment, including 336 bp of the preceding intron and the poly A signal. It also contains a strong promoter sequence from the MOPC 41 K gene, and the heavy chain enhancer sequence. There is a unique Xba I site between the promoter and the C intron.
  • the plasmid also contains the gpt gene for selection. Two other very similar plasmids were prepared by using the human 71 and 7 3 C regions in place of the K C region.
  • the region inserted between the Xba I and Bam HI sites extended form about 210 bp 5* of the CHI exon to about 1100 bp 3 ' of the CH3 exon.
  • the gpt gene was replaced with the hyg gene to confer resistance to hygromycin.
  • the next 16 nucleotides were the same as the sequence that follows JK5 in mouse genomic DNA, and therefore included a splice donor signal.
  • the final nucleotides of the oligo consisted of an Xba I site followed by a short irrelevant sequence.
  • This oligonucleotide was hybridized to the Ml3 phage DNA containing the K CDNA and extended with Klenow polymerase (Fig. 3) .
  • the DNA was denatured and hybridized to a "reverse primer," which represents M13 DNA 5' to the cDNA insert.
  • the reverse primer was extended, and the DNA cut with Xba I.
  • the Xba I fragment consisting of the extended VJ segment of the cDNA was purified, and cloned in the correction orientation into the Xba I site of pV ⁇ l to obtain the plasmid pLTAC2 (Fig. 7) .
  • the final chimeric K gene has a VJ-C intron, of which the first 14 bp and last 209 bp are respectively the same as in mouse and human genomic DNA, as verified by direct sequencing of the construct.
  • the gene is transcribed from a K promoter, stimulated by the heavy chain enhancer. Based on results obtained with deleted introns, we expected that the intron would be correctly spliced from the transcribed RNA.
  • the VJ region from the anti-Tac 72a heavy chain cDNA, followed by a splice donor signal was inserted into the Xba I site of pV 7 lneo.
  • the resulting plasmid pHTAC contains a chimeric heavy chain gene, with a synthetic intron between the mouse VJ and human C 7 I segments.
  • RF DNA of the phage M13mpll was cut with Eco Rl and Xba I, the ends were filled-in, and the DNA ligated was ligated and transformed into JM101 cells. A plaque was picked and the DNA was sequenced to verify that the ends of the DNA had joined correctly, recreating the Eco Rl and Xba I sites with the intervening DNA segment deleted. This phage is designated M13mpllD. Eco Rl fragments containing the anti-Tac light and heavy chain cDNAs were separately cloned into the Eco Rl site of M13mpll, so that their 5' ends aubbed the Xba I site. The resulting phage are respectively denoted M13mpllL and M13mpllH.
  • the following 48-nucleotide long primer was synthesized and gel-purified: CCAGAATTCTAGAAAAGTGTACTTACGTTTCAGCTCCAGCTTGGTCCC. From the 3' end, the first 22 residues of the primer are the same as the last 22 bp of the JK5 segment (non-coding strand) . The next 16 nucleotides are the same as the sequence that follows JK5 in mouse genomic DNA and therefore includes a splice donor signal (abbreviated SD in Fig. 11) . The final nucleotides of the oligo consist of an Xba I site followed by a short irrelevant sequence.
  • Klenow polymerase The solution was incubated for 30 minutes at 37 X C. 50 ng of the "reverse primer" AACAGCTATGACCATG (New England Biolabs) , which can hybridize to the newly synthesized strand upstream of the Xba I site (Fig. 11) , was added. The solution was incubated at 95 ⁇ C for 3 min and put on ice. An additional 4 ul of 200 uM each dNTP and 5u Klenow polymerase was added, and the solution incubated for 30 minutes at 37 C. The solution was extracted with phenol- chloroform, precipitated with ethanol, resuspended, and digested with 20u Xba I.
  • AACAGCTATGACCATG New England Biolabs
  • the digested DNA was run on a 4% polyacrylamide gel and visualized with ethidiu bromide. In addition to high molecular weight DNA, an approximately 400 bp fragment was visible, corresponding to the VJ region of the light chain cDNA with a "tail" (Fig. 11) . The fragment was cloned directly into the Xba I site of pV ⁇ l in the correct orientation.
  • the first 21 residues of the primer are the same as the last 21 bp of the JH2 segment (non-coding strand) .
  • the next 19 nucleotides are the same as the sequence that follows JH2 in mouse genomic DNA and therefore includes a splice donor signal.
  • the final nucleotides of the oligo consist of an Xba I site followed by a short irrelevant sequence.
  • This primer was hybridized to M13mpllH DNA following the same protocol as above, in order to synthesize a fragment containing the VJ region of the heavy chain cDNA. The fragment was cloned directly into the Xba I site of pV 7 lneo in the correct orientation.
  • Chimeric Antibody Specificity CR2-2 and CEM cells are human T cell lines that are respectively positive and negative for surface expression of the IL2 receptor (IL2R) .
  • Whole CR2-2 cells were used to demonstrate binding specificity of the chimeric antibody in an ELISA assay, and CEM cells were used as a negative control.
  • IL2R IL2 receptor
  • Antibody to be tested was prepared in several ways.
  • Anti-Tac monoclonal antibody supplied by T. Waldmann, was purified from mouse ascites by passage through a DEAE-dextran column.
  • the cell line L40H4 created by transfecting SP2/0 cells with the chimeric light and gamma 1 heavy chain plasmids pLTAC2 and pGTACl (described above) , was injected into mice to form an ascites. From 3 mis of ascites fluid, 650 ⁇ g of chimeric gamma 1 antibody was purified by passage through a column of Baker Abx and a size exclusion column.
  • 2 x 10 6 cells were mixed with either purified antibody in 20 ⁇ l FACS buffer or 20 ⁇ l media supernatent from the transfected cell lines, and incubated on i ce f or 2 hr. The cells were washed 3 times with 1 ⁇ l of FACS buffer (being collected by brief centrifugation after each wash) .
  • the cells that had been incubated with anti-Tac antibody were mixed with 0.5 ⁇ l peroxidase-conjugated goat anti-mouse antibody (Fab) ' fragment (Tago Immunologicals, Burlingame, California) in 20 ⁇ l FACS buffer, and the cells that had been incubated with chimeric antibody were mixed with 0.5 ⁇ l peroxidase- conjugated goat anti-human gamma chain (Fab) ' fragment (Tago) in 20 ⁇ l FACS buffer.
  • the cells were incubated for 30 min on ice and then washed 3 times with FACS buffer. They were then mixed with 100 ⁇ l peroxidase development solution and incubated for 5 min at room temperature.
  • the cells were spun out and the supernatents were transferred to a 96-well plate and the OD's determined in an ELISA reader. The OD's at 414 nm for the cells treated with each antibody are given in Table l.
  • the anti-Tac antibody itself bound to the IL2R+ CR2-2 cells but not to the IL2R- CEM cells.
  • An equal amount of purified gamma 1 chimeric antibody gave an equivalent amount of binding to the CR2-2 cells as the anti- Tac, and also failed to bind to the CEM cells. All the supernatants from both the chimeric antibody producing cells bound to the CR2-2 cells. As additional negative controls, the 51.3 supernatant did not bind to the CEM cells, and supernatant from the parental SP2/0 cells did not bind the CR2-2 cells.
  • the plate was washed, incubated with peroxidase-conjugated goat anti-human gamma chain antibody, washed again, incubated with peroxidase developing solution and the OD's at 414 nm determined in an ELISA reader.
  • the media supernatants contained respectively about 8 and 7 ng per ⁇ l, that is the cells secreted 8 and 7 ⁇ g antibody per 10 6 cells per 24 hr.
  • the mixed lymphocyte reaction is a model for transplant rejection and was used to analyze the effectiveness of the chimeric anti-Tac antibodies.
  • Table 3 The experiments shown in Table 3 below were performed by standard methods (see, e.g. , Strong, D.M. et al., In Vitro Stimulation of Murine Spleen Cells Using a Microculture System and a .
  • the chimeric antibodies of the present invention offer numerous advantages of other human IL-2 receptor-specific antibodies.
  • the present human chimeric antibodies can be more economically produced and contain substantially less foreign amino acid sequences. This reduced likelihood of antigenicity after injection into a human patient represents a significant therapeutic improvement.

Abstract

Des anticorps chimériques réagissant de manière spécifique aux récepteurs d'IL-2 humaine sont préparés par l'utilisation d'une technologie d'ADN recombinant que l'on utilise par exemple pour le traitement de troubles induits par des cellules T.
PCT/US1989/001578 1988-04-15 1989-04-13 Anticorps chimeriques specifiques au recepteur il-2 WO1989009622A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019890702368A KR900700134A (ko) 1988-04-15 1989-04-13 Il-2 수용체-특이적 키메릭 항체
FI895955A FI895955A0 (fi) 1988-04-15 1989-12-13 Il-2-receptorspecifika chimera antikroppar.
NO89895022A NO895022L (no) 1988-04-15 1989-12-14 Il-2 reseptorspesifikke chimere antistoffer.
DK631689A DK631689A (da) 1988-04-15 1989-12-14 Il-2 receptor-specifikke kimaeriske antistoffer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18186288A 1988-04-15 1988-04-15
US181,862 1988-04-15

Publications (1)

Publication Number Publication Date
WO1989009622A1 true WO1989009622A1 (fr) 1989-10-19

Family

ID=22666118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/001578 WO1989009622A1 (fr) 1988-04-15 1989-04-13 Anticorps chimeriques specifiques au recepteur il-2

Country Status (6)

Country Link
EP (1) EP0362371A4 (fr)
JP (1) JPH02503867A (fr)
KR (1) KR900700134A (fr)
AU (1) AU631545B2 (fr)
FI (1) FI895955A0 (fr)
WO (1) WO1989009622A1 (fr)

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0380068A1 (fr) * 1989-01-24 1990-08-01 Miles Inc. Système d'expression pour la production d'anticorps monoclonaux chimériques
FR2649488A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Fragments d'anticorps monoclonaux specifiques de la presence de leucocytes actives - leur procede d'obtention et leur application dans le cas de rejet de greffe
EP0421876A1 (fr) * 1989-10-06 1991-04-10 PASTEUR MERIEUX SERUMS ET VACCINS, Société Anonyme : Application d'agents actifs pour la préparation d'un médicament destiné au traitement de lymphomes ou assimilés
FR2652747A1 (fr) * 1989-10-06 1991-04-12 Merieux Inst Application d'agents actifs pour la preparation d'un medicament destine au traitement de maladies auto-immunes.
EP0449769A1 (fr) * 1990-03-16 1991-10-02 Sandoz Ltd. Molécules liant à la CD25
EP0451216A1 (fr) * 1988-12-28 1991-10-16 Protein Design Labs Inc IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2.
EP0460674A2 (fr) * 1990-06-08 1991-12-11 Roche Diagnostics GmbH ADN recombinant et procédé de production des anticorps chimériques
WO1992004051A1 (fr) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh Anticorps monoclonaux du recepteur d'interleukine-2
GR900100009A (en) * 1990-01-09 1992-06-25 Protein Design Labs Particular human immunoglobulin receiver of il-2 new type
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
WO1997017374A1 (fr) * 1995-11-08 1997-05-15 Medac Gesellschaft Für Klinische Spezialpräparate Gmbh Ligands de recombinaison pour l'antigene cd30 de la membrane cellulaire humaine
WO1997028828A1 (fr) 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprenant un inhibiteur de l'interleukine 1 et un polymere a liberation controlee
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO2000006604A2 (fr) * 1998-07-27 2000-02-10 Novartis Ag Molecules de liaison cd25 utilisees pour traiter la polyarthrite rhumatoide ou les maladies cutanees
US6054297A (en) * 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
WO2000069459A1 (fr) 1999-05-14 2000-11-23 Imclone Systems Incorporated Traitement de tumeurs humaines refractaires avec des antagonistes de recepteurs du facteur de croissance epidermique
WO2001002853A2 (fr) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION D'ACTIVITE DU FACTEUR VON WILLEBRAND (vWF)
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO2004002421A2 (fr) 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de traitement de la sclerose en plaques
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6890532B2 (en) 2000-05-16 2005-05-10 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
WO2005042581A2 (fr) 2003-11-01 2005-05-12 Biovation Ltd. Anticorps anti-cd52 modifie
WO2005116657A2 (fr) 2004-05-24 2005-12-08 Universität Zu Köln Identification d'un transporteur d'ergothioneine et ses utilisations therapeutiques
WO2006021893A2 (fr) 2004-08-26 2006-03-02 The University Of Western Ontario Cibles bacteriennes d'acquisition de fer
WO2006034507A2 (fr) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methodes de diagnostic et de traitement lors de complications de la grossesse
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
WO2006083355A2 (fr) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Utilisation des cellules du recepteur du facteur de croissance endothelial vasculaire dans le traitement et la surveillance du cancer et dans le criblage d'agents chimiotherapeutiques
US7098006B1 (en) 1990-09-17 2006-08-29 Burroughs Wellcome Co. Chimeric antibody, pharmaceutical composition and process of its production
WO2006105448A2 (fr) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation de cellules exprimant la muc1
EP1724282A2 (fr) 1997-05-21 2006-11-22 Biovation Limited Procédé de production de protéines non-immunogènes
WO2007027751A2 (fr) 2005-08-30 2007-03-08 University Of Miami Immunomodulation des agonistes, des antagonistes et des immunotoxines du recepteur 25 du facteur de necrose tumorale (tnfr25)
US7252823B2 (en) * 1991-03-18 2007-08-07 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
EP1923702A2 (fr) 2004-06-04 2008-05-21 University of Geneva Nouveaux supports et procédés pour le traitement de perte de l'acuité auditive et écoute fantôme
WO2008081008A1 (fr) 2007-01-05 2008-07-10 University Of Zurich Procédé pour fournir des molécules de liaison et des cibles spécifiques à une maladie.
WO2008110372A1 (fr) 2007-03-13 2008-09-18 University Of Zurich Anticorps monoclonal humain spécifique d'une tumeur
WO2008118324A2 (fr) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
EP1998266A2 (fr) 2001-02-19 2008-12-03 Merck Patent GmbH Procédé d'identification d'épitopes de cellules T et utilisation pour préparer des molécules avec immunogénicité réduite
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
WO2009014835A2 (fr) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Toxines modifiées
EP2070947A1 (fr) 2003-12-05 2009-06-17 multimmune GmbH Anticorps anti-Hsp70 thérapeutiques et de diagnostic
EP2100618A2 (fr) 2005-06-17 2009-09-16 Imclone LLC Antagonistes de PDGFR-alpha pour le traitement du cancer osseux métastatique
WO2010027364A1 (fr) 2008-09-07 2010-03-11 Glyconex Inc. Anticorps anti-glycosphingolipide de type i étendu, dérivés de celui-ci et utilisation
EP2172220A1 (fr) 2004-02-04 2010-04-07 Beth Israel Deaconess Medical Center Procédés de diagnostic et de traitement de pré-éclampsie ou éclampsie
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2010069603A1 (fr) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Auto-anticorps humains anti-alpha-synucléine
US7744885B2 (en) 1991-03-18 2010-06-29 Centocor, Inc. Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereof
WO2011015379A1 (fr) 2009-08-05 2011-02-10 Nexigen Gbmh Protéines interagissant avec le hcv humain et procédés d'utilisation
EP2287339A1 (fr) 2004-05-18 2011-02-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
WO2011024114A1 (fr) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Molécules de matrice extracellulaire de ciblage pour le traitement du cancer
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
EP2305301A2 (fr) 2002-07-19 2011-04-06 Beth Israel Deaconess Medical Center Procédés de diagnostic et de traitement de pre-eclampsie ou d'eclampsie
WO2011039724A1 (fr) 2009-10-02 2011-04-07 Sanofi-Aventis Anticorps qui se lient spécifiquement au récepteur epha2
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
EP2332990A1 (fr) 2004-03-19 2011-06-15 Imclone LLC Anticorps de récepteur de facteur de croissance anti-épidermique humain
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
WO2011103389A1 (fr) 2010-02-19 2011-08-25 Cornell University Procédé pour traiter des maladies démyélinisantes auto-immunes et d'autres maladies auto-immunes ou inflammatoires
US8008007B2 (en) 2005-04-14 2011-08-30 Rwth Aachen S-adenosyl-L-methionine analogs with extended activated groups for transfer by methyltransferases
EP2363410A1 (fr) 2002-11-27 2011-09-07 Minerva Biotechnologies Corporation Isoformes de MUC1
EP2365001A2 (fr) 2003-05-01 2011-09-14 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
WO2011123381A1 (fr) 2010-04-01 2011-10-06 Imclone Llc Anticorps contre le csf-1r
EP2377555A2 (fr) 2004-11-18 2011-10-19 Imclone LLC Anticorps contre le récepteur 1 du facteur de croissance endothéliale vasculaire
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
WO2011145085A2 (fr) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer
US8071099B2 (en) 2008-05-30 2011-12-06 ImClone, LLC Anti-FLT3 antibodies
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
WO2012025636A1 (fr) 2010-08-27 2012-03-01 University Of Zurich Procédé de validation de cibles et de médicaments pour des affections inflammatoires et/ou cardiovasculaires
WO2012028697A1 (fr) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Système de purification par affinité sur la base d'une complémentation de brin de donneur
EP2433966A1 (fr) 2006-11-03 2012-03-28 U3 Pharma GmbH Anticorps FGFR4
US8153765B2 (en) 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer
WO2012049570A1 (fr) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Anticorps anti-tau humain
WO2012052230A1 (fr) 2010-10-18 2012-04-26 Mediapharma S.R.L. Anticorps se liant à erbb3
WO2012080518A1 (fr) 2010-12-17 2012-06-21 Neurimmune Holding Ag Anticorps humains anti-sod1
WO2012104824A1 (fr) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Anticorps thérapeutiques ciblant app-c99
WO2012113775A1 (fr) 2011-02-21 2012-08-30 University Of Zurich Ankyrine g et ses modulateurs pour le traitement de troubles neurodégénératifs
WO2012125775A1 (fr) 2011-03-16 2012-09-20 Sanofi Utilisations d'une protéine de type anticorps à région v double
EP2527369A2 (fr) 2007-09-13 2012-11-28 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
EP2530088A1 (fr) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Supports et procédés de diagnostic et de traitement de la sclérose en plaques
WO2012177972A1 (fr) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Molécules de liaison anti-alpha-synucléine
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US8388965B2 (en) 2007-10-15 2013-03-05 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
WO2013041962A1 (fr) 2011-09-19 2013-03-28 Axon Neuroscience Se Thérapie protéique et diagnostic d'une pathologie à médiation par tau dans la maladie d'alzheimer
WO2013050540A1 (fr) 2011-10-05 2013-04-11 University Of Bremen Wnt4 et med12 pour l'utilisation dans le diagnostic et le traitement de maladies tumorales
US8460667B2 (en) 2006-07-18 2013-06-11 Sanofi EPHA2 receptor antagonist antibodies
EP2602621A1 (fr) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, nouveau marqueur urinaire pour la détection du carcinome cellulaire transitionnel
WO2013093122A2 (fr) 2011-12-23 2013-06-27 Phenoquest Ag Anticorps pour le traitement et le diagnostic de troubles affectifs et de l'anxiété
WO2013098419A1 (fr) 2011-12-28 2013-07-04 Immunoqure Ag Méthode pour fournir des auto-anticorps monoclonaux à spécificité désirée
WO2013149526A1 (fr) 2012-04-01 2013-10-10 上海益杰生物技术有限公司 Polypeptide anticorps multifonctionnel pour un épitope cryptique d'un récepteur du facteur de croissance épidermique et d'un antigène de lymphocyte t
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
EP2711016A1 (fr) 2012-09-21 2014-03-26 Covagen AG Nouvelles molécules de liaison IL-17A et leurs utilisations médicales
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014102399A1 (fr) 2012-12-31 2014-07-03 Neurimmune Holding Ag Anticorps humains recombinants destinés à la thérapie et à la prévention de maladies associées aux polyomavirus
WO2014180306A1 (fr) 2013-05-08 2014-11-13 上海益杰生物技术有限公司 Acide nucléique d'une protéine récepteur d'antigène chimérique de gpc3 codée et lymphocyte t exprimant une protéine récepteur d'antigène chimérique de gpc3
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2015106641A1 (fr) 2014-01-15 2015-07-23 上海易乐生物技术有限公司 Anticorps monoclonal probdnf antihumain et ses utilisations pour des douleurs
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules
EP2918605A1 (fr) 2007-11-12 2015-09-16 U3 Pharma GmbH Anticorps axl
US9150650B2 (en) 2007-06-13 2015-10-06 Pharmabcine Inc. Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
US9163086B2 (en) 2009-08-18 2015-10-20 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
WO2015198146A2 (fr) 2014-06-27 2015-12-30 Sanofi Anticorps bispécifiques anti-il4-il13
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2016050822A2 (fr) 2014-09-30 2016-04-07 Neurimmune Holding Ag Anticorps dirigés contre des répétitions dipeptidiques (dpr) d'origine humaine
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2016081796A1 (fr) 2014-11-21 2016-05-26 Yale University Compositions et procédés pour moduler salm5 et hvem
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2016140910A2 (fr) 2015-03-04 2016-09-09 University Of Rochester Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016149621A1 (fr) 2015-03-18 2016-09-22 The Johns Hopkins University Nouveaux inhibiteurs d'anticorps monoclonaux ciblant le canal potassique kcnk9
WO2016146702A1 (fr) 2015-03-16 2016-09-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Molécules de liaison trispécifiques pour le traitement d'une infection par le vhb et d'états pathologiques associés
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3202788A1 (fr) 2016-02-05 2017-08-09 MediaPharma S.r.l. Anticorps à liaison d'endosialin
WO2017167967A1 (fr) 2016-04-01 2017-10-05 Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. Anticorps ciblant l'erbb2
EP3269740A1 (fr) 2016-07-13 2018-01-17 Mabimmune Diagnostics AG Nouveaux agents de liaison de protéine activatrice d'anti-fibroblaste (fap) et leurs utilisations
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
WO2018083282A1 (fr) 2016-11-07 2018-05-11 Biouniversa S.R.L. Anticorps anti-bag3 en combinaison avec des inhibiteurs du point de contrôle immunitaire à usage thérapeutique
WO2018129029A1 (fr) 2017-01-04 2018-07-12 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
WO2018172465A1 (fr) 2017-03-22 2018-09-27 Sanofi Traitement du lupus à l'aide d'anticorps anti-cxcr5 humanisés
WO2018185050A1 (fr) 2017-04-03 2018-10-11 Covagen Ag Molécules de liaison à fgfr3
US10183965B2 (en) 2014-08-29 2019-01-22 Katholieke Universiteit Leuven Cofactor analogues for methyltransferases
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10345298B2 (en) 2014-04-30 2019-07-09 Klinikum Rechts Der Isar Der Technischen Universität München Diagnosis of multiple sclerosis
US10377822B2 (en) 2014-07-17 2019-08-13 Carsgen Therapeutics Ltd. Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
WO2019207159A1 (fr) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Anticorps dirigé contre un peptide neurotoxique dérivé de tau et ses utilisations
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
WO2020053808A1 (fr) 2018-09-12 2020-03-19 Georg Dewald Procédé de diagnostic de troubles vasorégulateurs
WO2020099235A1 (fr) 2018-11-12 2020-05-22 Mediapharma S.R.L. Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3
US10703821B2 (en) 2005-03-30 2020-07-07 Minerva Biotechnologies Corporation Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor
WO2020157122A1 (fr) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Traitement de l'agent causal de l'angiogenèse
EP3693387A1 (fr) 2015-11-05 2020-08-12 Intrepida Bio, Inc. Anticorps anti-bag3 humanisés
WO2020167912A1 (fr) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anticorps de type adressine anti-ganglions lymphatiques périphériques et leurs utilisations
EP3699284A1 (fr) 2012-07-05 2020-08-26 The Trustees of the University of Pennsylvania Anticorps u1 snrnp de régulation de l'expression génique et de modulation de l'oncogénicité
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2020242989A1 (fr) 2019-05-24 2020-12-03 Sanofi Méthodes de traitement de la sclérodermie généralisée
EP3792278A2 (fr) 2012-12-21 2021-03-17 Biogen MA Inc. Anticorps anti-tau humains
WO2021140173A1 (fr) 2020-01-10 2021-07-15 Biouniversa S.R.L. Méthodes et utilisations pour le traitement de tumeurs fibreuses solides avec des inhibiteurs de bags
WO2021183207A1 (fr) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions et procédés pour l'immunothérapie du cancer positif à npm1c
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
EP4056591A1 (fr) 2013-07-03 2022-09-14 ImmunoQure AG Anticorps anti-ifn-alpha humains
WO2022189632A1 (fr) 2021-03-12 2022-09-15 Fibrosys S.R.L. Anticorps monoclonaux pour le traitement d'infections virales
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
US11898160B2 (en) 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173494A2 (fr) * 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0184187A2 (fr) * 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
EP0125023B1 (fr) * 1983-04-08 1991-06-05 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US664911A (en) * 1900-09-17 1901-01-01 William H Voss Mechanical movement.
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125023B1 (fr) * 1983-04-08 1991-06-05 Genentech, Inc. Préparations d'immunoglobuline recombinante, méthodes pour leur préparation, séquences d'ADN, vecteurs d'expression et cellules d'hôtes recombinantes
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
EP0173494A2 (fr) * 1984-08-27 1986-03-05 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
EP0184187A2 (fr) * 1984-12-04 1986-06-11 Teijin Limited Chaîne lourde d'immunoglobuline chimère souris-humaine et chimère de l'ADN codant celle-ci

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP0362371A4 *
The Journal of Immunology, Vol. 126, No. 4, issued April 1981 (USA), UCHIYAMA et al, "A Monoclonal Antibody (ANTI-Tac) Reactive with Activated and Functionally Mature Human T Cells," see pages 1393 to 1397. *

Cited By (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022500B1 (en) 1988-12-28 2006-04-04 Protein Design Labs, Inc. Humanized immunoglobulins
EP1477497B1 (fr) * 1988-12-28 2014-11-26 PDL BioPharma, Inc. Procédé de production d' anticorps humanisés
EP0451216A1 (fr) * 1988-12-28 1991-10-16 Protein Design Labs Inc IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2.
EP0451216A4 (en) * 1988-12-28 1992-01-02 Protein Design Labs, Inc. Chimeric immunoglobulins specific for p55 tac protein of the il-2 receptor
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
EP0380068A1 (fr) * 1989-01-24 1990-08-01 Miles Inc. Système d'expression pour la production d'anticorps monoclonaux chimériques
FR2649488A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Fragments d'anticorps monoclonaux specifiques de la presence de leucocytes actives - leur procede d'obtention et leur application dans le cas de rejet de greffe
WO1991000921A1 (fr) * 1989-07-07 1991-01-24 Institut National De La Sante Et De La Recherche Medicale Fragments d'anticorps monoclonaux specifiques de la presence de leucocytes actives - leur procede d'obtention et leur application dans le cas de rejet de greffe
US8163522B1 (en) 1989-09-12 2012-04-24 Hoffman-Laroche Inc. Human TNF receptor
US8063182B1 (en) 1989-09-12 2011-11-22 Hoffman-Laroche Inc. Human TNF receptor fusion protein
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US5338669A (en) * 1989-09-20 1994-08-16 Abbott Biotech, Incorporated Method of producing fusion proteins
FR2652746A1 (fr) * 1989-10-06 1991-04-12 Merieux Inst Application d'agents actifs pour la preparation d'un medicament destine au traitement de lymphomes ou assimiles.
FR2652747A1 (fr) * 1989-10-06 1991-04-12 Merieux Inst Application d'agents actifs pour la preparation d'un medicament destine au traitement de maladies auto-immunes.
EP0421876A1 (fr) * 1989-10-06 1991-04-10 PASTEUR MERIEUX SERUMS ET VACCINS, Société Anonyme : Application d'agents actifs pour la préparation d'un médicament destiné au traitement de lymphomes ou assimilés
GR900100009A (en) * 1990-01-09 1992-06-25 Protein Design Labs Particular human immunoglobulin receiver of il-2 new type
US6521230B1 (en) 1990-03-16 2003-02-18 Novartis Ag CD25 binding molecules
EP0449769A1 (fr) * 1990-03-16 1991-10-02 Sandoz Ltd. Molécules liant à la CD25
US6383487B1 (en) * 1990-03-16 2002-05-07 Novartis Ag Methods of treatment using CD25 binding molecules
EP0460674A3 (en) * 1990-06-08 1992-08-19 Boehringer Mannheim Gmbh Recombinant dna and process for the production of chimaeric antibodies
EP0460674A2 (fr) * 1990-06-08 1991-12-11 Roche Diagnostics GmbH ADN recombinant et procédé de production des anticorps chimériques
WO1992004051A1 (fr) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh Anticorps monoclonaux du recepteur d'interleukine-2
US6538110B1 (en) 1990-09-12 2003-03-25 Roche Diagnostics Monoclonal antibodies against the interleukin 2 receptor
US7098006B1 (en) 1990-09-17 2006-08-29 Burroughs Wellcome Co. Chimeric antibody, pharmaceutical composition and process of its production
USRE46877E1 (en) 1990-09-17 2018-05-29 Btg International Limited Altered antibodies and their preparation
USRE43898E1 (en) 1990-09-17 2013-01-01 Glaxo Wellcome Inc. Research Altered antibodies and their preparation
US7252823B2 (en) * 1991-03-18 2007-08-07 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7276239B2 (en) 1991-03-18 2007-10-02 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7744885B2 (en) 1991-03-18 2010-06-29 Centocor, Inc. Methods of treating vascular inflammatory pathology using anti-TNF antibodies and fragments thereof
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US6054297A (en) * 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
US6719971B1 (en) 1991-06-14 2004-04-13 Genentech, Inc. Method for making humanized antibodies
US6639055B1 (en) 1991-06-14 2003-10-28 Genentech, Inc. Method for making humanized antibodies
US8075890B2 (en) 1991-06-14 2011-12-13 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6146631A (en) * 1991-11-04 2000-11-14 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5756699A (en) * 1991-11-04 1998-05-26 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US6649742B1 (en) 1991-11-04 2003-11-18 Xoma Technology Ltd. Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5744580A (en) * 1991-11-04 1998-04-28 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6376217B1 (en) 1991-11-04 2002-04-23 Xoma Technology Ltd. Fusion proteins and polynucleotides encoding gelonin sequences
US5821123A (en) * 1991-12-13 1998-10-13 Xoma Corporation Modified antibody variable domains
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5770196A (en) * 1991-12-13 1998-06-23 Xoma Corporation Modified antibody variable domains and therapeutic uses thereof
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
WO1997017374A1 (fr) * 1995-11-08 1997-05-15 Medac Gesellschaft Für Klinische Spezialpräparate Gmbh Ligands de recombinaison pour l'antigene cd30 de la membrane cellulaire humaine
WO1997028828A1 (fr) 1996-02-09 1997-08-14 Amgen Boulder Inc. Composition comprenant un inhibiteur de l'interleukine 1 et un polymere a liberation controlee
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
EP2002846A2 (fr) 1996-12-06 2008-12-17 Amgen Inc. Thérapie combinée utilisant un inhibiteur IL-1 pour traiter les maladies liées au IL-1
EP1724282A2 (fr) 1997-05-21 2006-11-22 Biovation Limited Procédé de production de protéines non-immunogènes
WO2000006604A3 (fr) * 1998-07-27 2000-06-15 Novartis Ag Molecules de liaison cd25 utilisees pour traiter la polyarthrite rhumatoide ou les maladies cutanees
WO2000006604A2 (fr) * 1998-07-27 2000-02-10 Novartis Ag Molecules de liaison cd25 utilisees pour traiter la polyarthrite rhumatoide ou les maladies cutanees
WO2000069459A1 (fr) 1999-05-14 2000-11-23 Imclone Systems Incorporated Traitement de tumeurs humaines refractaires avec des antagonistes de recepteurs du facteur de croissance epidermique
EP2042194A2 (fr) 1999-05-14 2009-04-01 Imclone Systems, Inc. Traitement des tumeurs humaines réfractaires avec des antagonistes de récepteur de facteur de croissance épidermique
EP2309275A1 (fr) 1999-07-05 2011-04-13 K.U.Leuven Research & Development Détection d'activité du facteur Von Willebrand (VWF)
WO2001002853A2 (fr) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION D'ACTIVITE DU FACTEUR VON WILLEBRAND (vWF)
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP2301579A1 (fr) 2000-01-28 2011-03-30 Sunnybrook Health Science Centre Procédé thérapeutique pour la réduction de l'angiogenèse
US6890532B2 (en) 2000-05-16 2005-05-10 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
EP1998266A2 (fr) 2001-02-19 2008-12-03 Merck Patent GmbH Procédé d'identification d'épitopes de cellules T et utilisation pour préparer des molécules avec immunogénicité réduite
EP1539200A2 (fr) * 2002-06-28 2005-06-15 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Procede de traitement de la sclerose multiple
EP3269377A1 (fr) * 2002-06-28 2018-01-17 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Procédé de traitement de la sclérose en plaques
WO2004002421A2 (fr) 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procede de traitement de la sclerose en plaques
US8298525B2 (en) 2002-06-28 2012-10-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist
EP2314627A3 (fr) * 2002-06-28 2011-05-11 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Procédé de traitement de la sclérose multiple
EP1539200A4 (fr) * 2002-06-28 2007-11-07 Us Gov Health & Human Serv Procede de traitement de la sclerose multiple
US7258859B2 (en) 2002-06-28 2007-08-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the treatment of multiple sclerosis
US8454965B2 (en) 2002-06-28 2013-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the treatment of multiple sclerosis
US7575742B2 (en) 2002-06-28 2009-08-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
EP2308507A2 (fr) 2002-07-19 2011-04-13 Beth Israel Deaconess Medical Center Procédés de diagnostic et de traitement de pre-eclampsie ou d'eclampsie
EP2305301A2 (fr) 2002-07-19 2011-04-06 Beth Israel Deaconess Medical Center Procédés de diagnostic et de traitement de pre-eclampsie ou d'eclampsie
EP2363410A1 (fr) 2002-11-27 2011-09-07 Minerva Biotechnologies Corporation Isoformes de MUC1
EP2365001A2 (fr) 2003-05-01 2011-09-14 Imclone LLC Anticorps humains dirigés contre le récepteur de facteur 1 de croissance de type insuline humaine
WO2005042581A2 (fr) 2003-11-01 2005-05-12 Biovation Ltd. Anticorps anti-cd52 modifie
EP2070947A1 (fr) 2003-12-05 2009-06-17 multimmune GmbH Anticorps anti-Hsp70 thérapeutiques et de diagnostic
EP2172220A1 (fr) 2004-02-04 2010-04-07 Beth Israel Deaconess Medical Center Procédés de diagnostic et de traitement de pré-éclampsie ou éclampsie
EP2332990A1 (fr) 2004-03-19 2011-06-15 Imclone LLC Anticorps de récepteur de facteur de croissance anti-épidermique humain
EP2287339A1 (fr) 2004-05-18 2011-02-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
EP3056571A1 (fr) 2004-05-18 2016-08-17 Georg Dewald Procédés et kits pour détecter un oedème de quincke héréditaire de type iii
WO2005116657A2 (fr) 2004-05-24 2005-12-08 Universität Zu Köln Identification d'un transporteur d'ergothioneine et ses utilisations therapeutiques
EP1923702A2 (fr) 2004-06-04 2008-05-21 University of Geneva Nouveaux supports et procédés pour le traitement de perte de l'acuité auditive et écoute fantôme
WO2006021893A2 (fr) 2004-08-26 2006-03-02 The University Of Western Ontario Cibles bacteriennes d'acquisition de fer
EP2347765A1 (fr) 2004-09-24 2011-07-27 Beth Israel Deaconess Medical Center Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
WO2006034507A2 (fr) 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methodes de diagnostic et de traitement lors de complications de la grossesse
US7655764B2 (en) 2004-09-24 2010-02-02 Amgen Inc. Modified Fc molecules
US7662931B2 (en) 2004-09-24 2010-02-16 Amgen Inc. Modified Fc molecules
US7645861B2 (en) 2004-09-24 2010-01-12 Amgen Inc. Modified Fc molecules
US7655765B2 (en) 2004-09-24 2010-02-02 Amgen Inc. Modified Fc molecules
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
EP2377555A2 (fr) 2004-11-18 2011-10-19 Imclone LLC Anticorps contre le récepteur 1 du facteur de croissance endothéliale vasculaire
US8143025B2 (en) 2004-11-18 2012-03-27 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
WO2006083355A2 (fr) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Utilisation des cellules du recepteur du facteur de croissance endothelial vasculaire dans le traitement et la surveillance du cancer et dans le criblage d'agents chimiotherapeutiques
EP2526957A2 (fr) 2005-03-30 2012-11-28 Minerva Biotechnologies Corporation Prolifération des cellules exprimant MUC1
EP2527365A2 (fr) 2005-03-30 2012-11-28 Minerva Biotechnologies Corporation Prolifération des cellules exprimant MUC1
US10703821B2 (en) 2005-03-30 2020-07-07 Minerva Biotechnologies Corporation Method for stimulating or enhancing proliferation of cells by activating the mucin 1 (MUC1) receptor
US8859495B2 (en) 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
WO2006105448A2 (fr) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation de cellules exprimant la muc1
US8008007B2 (en) 2005-04-14 2011-08-30 Rwth Aachen S-adenosyl-L-methionine analogs with extended activated groups for transfer by methyltransferases
EP2100618A2 (fr) 2005-06-17 2009-09-16 Imclone LLC Antagonistes de PDGFR-alpha pour le traitement du cancer osseux métastatique
EP2505205A1 (fr) 2005-06-17 2012-10-03 Imclone LLC Anticorps alpha anti-PDGFR
EP2100614A2 (fr) 2005-06-17 2009-09-16 Imclone LLC Antagonistes de PDGFR-alpha pour le traitement du cancer osseux métastatique
US10188740B2 (en) 2005-08-12 2019-01-29 Amgen Inc. Modified Fc molecules
US11266744B2 (en) 2005-08-12 2022-03-08 Amgen Inc. Modified Fc molecules
US9114175B2 (en) 2005-08-12 2015-08-25 Amgen Inc. Modified Fc molecules
WO2007027751A2 (fr) 2005-08-30 2007-03-08 University Of Miami Immunomodulation des agonistes, des antagonistes et des immunotoxines du recepteur 25 du facteur de necrose tumorale (tnfr25)
US8460667B2 (en) 2006-07-18 2013-06-11 Sanofi EPHA2 receptor antagonist antibodies
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
US10208122B2 (en) 2006-10-02 2019-02-19 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
US11858999B2 (en) 2006-10-02 2024-01-02 Amgen K-A, Inc. IL-17 receptor A antigen binding proteins
EP3165539A1 (fr) 2006-10-02 2017-05-10 Kirin-Amgen, Inc. Protéines se liant à des antigènes a du récepteur il-17
WO2008054603A2 (fr) 2006-10-02 2008-05-08 Amgen Inc. Protéines de liaison à l'antigène du récepteur a de l'il-17
US11180564B2 (en) 2006-10-02 2021-11-23 Amgen K-A, Inc. IL-17 Receptor A antigen binding proteins
EP3909980A1 (fr) 2006-10-19 2021-11-17 Sanofi Nouveaux anticorps anti-cd38 pour le traitement du cancer
EP3498735A1 (fr) 2006-10-19 2019-06-19 Sanofi Anticorps anti-cd38 pour le traitement de la leucemie
US8153765B2 (en) 2006-10-19 2012-04-10 Sanof Aventis Anti-CD38 antibodies for the treatment of cancer
EP2433966A1 (fr) 2006-11-03 2012-03-28 U3 Pharma GmbH Anticorps FGFR4
EP3239175A1 (fr) 2007-01-05 2017-11-01 University of Zurich Procédé pour fournir des molécules de liaison et des cibles spécifiques à une maladie
EP3239174A1 (fr) 2007-01-05 2017-11-01 University of Zurich Anticorps anti-amyloide et son utilisation
EP2426143A2 (fr) 2007-01-05 2012-03-07 University of Zurich Procédé pour fournir des molécules de liaison et des cibles spécifiques à une maladie
WO2008081008A1 (fr) 2007-01-05 2008-07-10 University Of Zurich Procédé pour fournir des molécules de liaison et des cibles spécifiques à une maladie.
EP2436696A1 (fr) 2007-01-05 2012-04-04 University of Zurich Procédé pour fournir des molécules de liaison et des cibles spécifiques à une maladie
WO2008110372A1 (fr) 2007-03-13 2008-09-18 University Of Zurich Anticorps monoclonal humain spécifique d'une tumeur
EP2457928A2 (fr) 2007-03-13 2012-05-30 Universität Zürich Anticorps monoclonal humain spécifique d'une tumeur
EP3159355A1 (fr) 2007-03-13 2017-04-26 Universität Zürich Anticorps monoclonal humain spécifique d'une tumeur
US8519106B2 (en) 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
WO2008118324A2 (fr) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib
US9150650B2 (en) 2007-06-13 2015-10-06 Pharmabcine Inc. Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
WO2009014835A2 (fr) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Toxines modifiées
US8252897B2 (en) 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
US8980262B2 (en) 2007-08-29 2015-03-17 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9815902B2 (en) 2007-08-29 2017-11-14 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
US8647622B2 (en) 2007-08-29 2014-02-11 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9175087B2 (en) 2007-08-29 2015-11-03 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9243067B2 (en) 2007-08-29 2016-01-26 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
US9228019B2 (en) 2007-08-29 2016-01-05 Sanofi Humanized anti-CXCR5 antibodies, derivatives thereof and their use
EP2527369A2 (fr) 2007-09-13 2012-11-28 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
EP2574630A1 (fr) 2007-10-15 2013-04-03 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
EP2573118A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
EP2574626A1 (fr) 2007-10-15 2013-04-03 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
US9738728B2 (en) 2007-10-15 2017-08-22 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2573117A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
EP2573119A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
US10759871B2 (en) 2007-10-15 2020-09-01 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2574629A1 (fr) 2007-10-15 2013-04-03 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
US9732162B2 (en) 2007-10-15 2017-08-15 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2573115A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
EP2573116A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
EP2573121A1 (fr) 2007-10-15 2013-03-27 Sanofi Anticorps liant IL-4 et/ou d'IL-13 et leurs utilisations
US8388965B2 (en) 2007-10-15 2013-03-05 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP3686220A1 (fr) 2007-10-15 2020-07-29 Sanofi Anticorps liant il-4 et/ou il-13 et leurs utilisations
US11453727B2 (en) 2007-10-15 2022-09-27 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
EP2918605A1 (fr) 2007-11-12 2015-09-16 U3 Pharma GmbH Anticorps axl
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
US8071099B2 (en) 2008-05-30 2011-12-06 ImClone, LLC Anti-FLT3 antibodies
WO2010027364A1 (fr) 2008-09-07 2010-03-11 Glyconex Inc. Anticorps anti-glycosphingolipide de type i étendu, dérivés de celui-ci et utilisation
US11898160B2 (en) 2008-10-09 2024-02-13 Minerva Biotechnologies Corporation Method for maintaining pluripotency in cells
WO2010069603A1 (fr) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Auto-anticorps humains anti-alpha-synucléine
EP2949666A1 (fr) 2008-12-19 2015-12-02 Biogen Idec International Neuroscience GmbH Anticorps humains anti-alpha-synucléine
EP3521309A1 (fr) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Anticorps humains anti-alpha-synucléine
WO2011015379A1 (fr) 2009-08-05 2011-02-10 Nexigen Gbmh Protéines interagissant avec le hcv humain et procédés d'utilisation
US9163086B2 (en) 2009-08-18 2015-10-20 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2011024114A1 (fr) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Molécules de matrice extracellulaire de ciblage pour le traitement du cancer
WO2011039282A1 (fr) 2009-09-29 2011-04-07 Julius-Maximilians-Universität Würzburg Moyens et procédés pour traiter des états ischémiques
EP2305285A1 (fr) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Supports et procédés pour traiter les conditions ischémiques
US8668910B2 (en) 2009-10-02 2014-03-11 Sanofi Antibodies that specifically bind to the EphA2 receptor
WO2011039724A1 (fr) 2009-10-02 2011-04-07 Sanofi-Aventis Anticorps qui se lient spécifiquement au récepteur epha2
US9676864B2 (en) 2009-10-02 2017-06-13 Sanofi Antibodies that specifically bind to the EphA2 receptor
WO2011046958A1 (fr) 2009-10-12 2011-04-21 Amgen Inc. Utilisation des proteines se liant a un antigene du recepteur a de l'il-17
US10808033B2 (en) 2010-01-15 2020-10-20 Amgen K-A, Inc. IL-17 receptor antibody formulation
US11505612B2 (en) 2010-01-15 2022-11-22 Amgen K-A, Inc. Method of treating diseases using an IL-17 receptor antibody formulation
US10072085B2 (en) 2010-01-15 2018-09-11 Kirin-Amgen, Inc. Method of treating psoriasis using an IL-17 receptor antibody formulation
WO2011100403A1 (fr) 2010-02-10 2011-08-18 Immunogen, Inc Anticorps anti-cd20 et utilisations de ceux-ci
WO2011103389A1 (fr) 2010-02-19 2011-08-25 Cornell University Procédé pour traiter des maladies démyélinisantes auto-immunes et d'autres maladies auto-immunes ou inflammatoires
WO2011123381A1 (fr) 2010-04-01 2011-10-06 Imclone Llc Anticorps contre le csf-1r
EP3156419A1 (fr) 2010-04-01 2017-04-19 ImClone LLC Anticorps anti-csf-1r
US8263079B2 (en) 2010-04-01 2012-09-11 ImClone, LLC Antibodies against CSF-1R
WO2011145085A2 (fr) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Nouveaux anticorps et procédés d'utilisation pour le traitement et le diagnostic du cancer
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9447164B2 (en) 2010-08-06 2016-09-20 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
WO2012025636A1 (fr) 2010-08-27 2012-03-01 University Of Zurich Procédé de validation de cibles et de médicaments pour des affections inflammatoires et/ou cardiovasculaires
WO2012028697A1 (fr) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Système de purification par affinité sur la base d'une complémentation de brin de donneur
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9701965B2 (en) 2010-10-01 2017-07-11 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9334328B2 (en) 2010-10-01 2016-05-10 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2012049570A1 (fr) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Anticorps anti-tau humain
WO2012052230A1 (fr) 2010-10-18 2012-04-26 Mediapharma S.R.L. Anticorps se liant à erbb3
WO2012080518A1 (fr) 2010-12-17 2012-06-21 Neurimmune Holding Ag Anticorps humains anti-sod1
EP3628689A1 (fr) 2010-12-17 2020-04-01 Neurimmune Holding AG Anticorps anti-sod1 humains
WO2012104824A1 (fr) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Anticorps thérapeutiques ciblant app-c99
WO2012113775A1 (fr) 2011-02-21 2012-08-30 University Of Zurich Ankyrine g et ses modulateurs pour le traitement de troubles neurodégénératifs
WO2012125775A1 (fr) 2011-03-16 2012-09-20 Sanofi Utilisations d'une protéine de type anticorps à région v double
US11008389B2 (en) 2011-03-16 2021-05-18 Sanofi Uses of a dual V region antibody-like protein
EP3235508A1 (fr) 2011-03-16 2017-10-25 Sanofi Compositions comprenant une protéine double de type anticorps de région variable
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US9533047B2 (en) 2011-03-31 2017-01-03 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
EP2530088A1 (fr) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Supports et procédés de diagnostic et de traitement de la sclérose en plaques
WO2012163765A1 (fr) 2011-05-30 2012-12-06 Klinikum Rechts Der Isar Der Technischen Universität München Moyens et procédés de diagnostic et de traitement de la sclérose en plaques
WO2012177972A1 (fr) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Molécules de liaison anti-alpha-synucléine
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3275461A1 (fr) 2011-09-19 2018-01-31 Axon Neuroscience SE Thérapie protéique et diagnostic d'une pathologie à médiation par tau dans la maladie d'alzheimer
WO2013041962A1 (fr) 2011-09-19 2013-03-28 Axon Neuroscience Se Thérapie protéique et diagnostic d'une pathologie à médiation par tau dans la maladie d'alzheimer
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013050540A1 (fr) 2011-10-05 2013-04-11 University Of Bremen Wnt4 et med12 pour l'utilisation dans le diagnostic et le traitement de maladies tumorales
EP2602621A1 (fr) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, nouveau marqueur urinaire pour la détection du carcinome cellulaire transitionnel
WO2013083690A1 (fr) 2011-12-08 2013-06-13 Julius-Maximilians-Universität Würzburg Lasp-1, nouveau marqueur urinaire pour la détection d'un carcinome à cellules de transition
US9186372B2 (en) 2011-12-16 2015-11-17 Moderna Therapeutics, Inc. Split dose administration
US9295689B2 (en) 2011-12-16 2016-03-29 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
US9271996B2 (en) 2011-12-16 2016-03-01 Moderna Therapeutics, Inc. Formulation and delivery of PLGA microspheres
WO2013093122A2 (fr) 2011-12-23 2013-06-27 Phenoquest Ag Anticorps pour le traitement et le diagnostic de troubles affectifs et de l'anxiété
EP3546481A2 (fr) 2011-12-28 2019-10-02 ImmunoQure AG Anticorps anti-interleukine 22 (il-22) et leurs utilisations
WO2013098419A1 (fr) 2011-12-28 2013-07-04 Immunoqure Ag Méthode pour fournir des auto-anticorps monoclonaux à spécificité désirée
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10525130B2 (en) 2012-03-26 2020-01-07 Sanofi Stable IGG4 based binding agent formulations
US10023639B2 (en) 2012-04-01 2018-07-17 Carsgen Therapeutics Co., Ltd. Multi-functional antibody polypeptide for cryptic epitope of epidermal growth factor receptor and T cell antigen
WO2013149526A1 (fr) 2012-04-01 2013-10-10 上海益杰生物技术有限公司 Polypeptide anticorps multifonctionnel pour un épitope cryptique d'un récepteur du facteur de croissance épidermique et d'un antigène de lymphocyte t
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9675668B2 (en) 2012-04-02 2017-06-13 Moderna Therapeutics, Inc. Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9095552B2 (en) 2012-04-02 2015-08-04 Moderna Therapeutics, Inc. Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9107886B2 (en) 2012-04-02 2015-08-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding basic helix-loop-helix family member E41
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9114113B2 (en) 2012-04-02 2015-08-25 Moderna Therapeutics, Inc. Modified polynucleotides encoding citeD4
US9149506B2 (en) 2012-04-02 2015-10-06 Moderna Therapeutics, Inc. Modified polynucleotides encoding septin-4
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9301993B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides encoding apoptosis inducing factor 1
US9216205B2 (en) 2012-04-02 2015-12-22 Moderna Therapeutics, Inc. Modified polynucleotides encoding granulysin
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9220755B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9221891B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. In vivo production of proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9233141B2 (en) 2012-04-02 2016-01-12 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9220792B2 (en) 2012-04-02 2015-12-29 Moderna Therapeutics, Inc. Modified polynucleotides encoding aquaporin-5
EP3699284A1 (fr) 2012-07-05 2020-08-26 The Trustees of the University of Pennsylvania Anticorps u1 snrnp de régulation de l'expression génique et de modulation de l'oncogénicité
EP4148135A1 (fr) 2012-07-05 2023-03-15 The Trustees of the University of Pennsylvania Anticorps u1 snrnp de régulation de l'expression génique et de modulation de l'oncogénicité
US11931380B2 (en) 2012-09-04 2024-03-19 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
EP2711016A1 (fr) 2012-09-21 2014-03-26 Covagen AG Nouvelles molécules de liaison IL-17A et leurs utilisations médicales
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3792278A2 (fr) 2012-12-21 2021-03-17 Biogen MA Inc. Anticorps anti-tau humains
WO2014102399A1 (fr) 2012-12-31 2014-07-03 Neurimmune Holding Ag Anticorps humains recombinants destinés à la thérapie et à la prévention de maladies associées aux polyomavirus
EP3517545A1 (fr) 2012-12-31 2019-07-31 Neurimmune Holding AG Anticorps humains recombinants pour la thérapie et la prévention de maladies associées au virus du polyome
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
WO2014180306A1 (fr) 2013-05-08 2014-11-13 上海益杰生物技术有限公司 Acide nucléique d'une protéine récepteur d'antigène chimérique de gpc3 codée et lymphocyte t exprimant une protéine récepteur d'antigène chimérique de gpc3
EP4056591A1 (fr) 2013-07-03 2022-09-14 ImmunoQure AG Anticorps anti-ifn-alpha humains
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015106641A1 (fr) 2014-01-15 2015-07-23 上海易乐生物技术有限公司 Anticorps monoclonal probdnf antihumain et ses utilisations pour des douleurs
WO2015153144A1 (fr) 2014-03-31 2015-10-08 Kirin-Amgen, Inc. Procédés de traitement du psoriasis des ongles et du cuir chevelu
US10345298B2 (en) 2014-04-30 2019-07-09 Klinikum Rechts Der Isar Der Technischen Universität München Diagnosis of multiple sclerosis
US11136388B2 (en) 2014-06-27 2021-10-05 Sanofi Biomarkers for anti-IL4-IL13 bispecific antibodies
WO2015198146A2 (fr) 2014-06-27 2015-12-30 Sanofi Anticorps bispécifiques anti-il4-il13
US11198729B2 (en) 2014-07-17 2021-12-14 Cafa Therapeutics Limited Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
US10377822B2 (en) 2014-07-17 2019-08-13 Carsgen Therapeutics Ltd. Immunologic effector cell of targeted CLD18A2, and preparation method and use thereof
US10183965B2 (en) 2014-08-29 2019-01-22 Katholieke Universiteit Leuven Cofactor analogues for methyltransferases
WO2016050822A2 (fr) 2014-09-30 2016-04-07 Neurimmune Holding Ag Anticorps dirigés contre des répétitions dipeptidiques (dpr) d'origine humaine
WO2016081796A1 (fr) 2014-11-21 2016-05-26 Yale University Compositions et procédés pour moduler salm5 et hvem
WO2016140910A2 (fr) 2015-03-04 2016-09-09 University Of Rochester Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016146702A1 (fr) 2015-03-16 2016-09-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Molécules de liaison trispécifiques pour le traitement d'une infection par le vhb et d'états pathologiques associés
WO2016149621A1 (fr) 2015-03-18 2016-09-22 The Johns Hopkins University Nouveaux inhibiteurs d'anticorps monoclonaux ciblant le canal potassique kcnk9
US10889644B2 (en) 2015-11-05 2021-01-12 Biouniversa S.R.L. Humanized anti-BAG3 antibodies
EP3693387A1 (fr) 2015-11-05 2020-08-12 Intrepida Bio, Inc. Anticorps anti-bag3 humanisés
US11318210B2 (en) 2016-02-05 2022-05-03 Fusion Pharmaceuticals Inc. Endosialin-binding antibody
EP3202788A1 (fr) 2016-02-05 2017-08-09 MediaPharma S.r.l. Anticorps à liaison d'endosialin
WO2017167967A1 (fr) 2016-04-01 2017-10-05 Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. Anticorps ciblant l'erbb2
EP3269740A1 (fr) 2016-07-13 2018-01-17 Mabimmune Diagnostics AG Nouveaux agents de liaison de protéine activatrice d'anti-fibroblaste (fap) et leurs utilisations
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
WO2018083282A1 (fr) 2016-11-07 2018-05-11 Biouniversa S.R.L. Anticorps anti-bag3 en combinaison avec des inhibiteurs du point de contrôle immunitaire à usage thérapeutique
WO2018129029A1 (fr) 2017-01-04 2018-07-12 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
US10842869B2 (en) 2017-03-22 2020-11-24 Sanofi Method of treating lupus by administering humanized anti-CXCR5 (C-X-C motif chemokine receptor 5) antibodies
WO2018172465A1 (fr) 2017-03-22 2018-09-27 Sanofi Traitement du lupus à l'aide d'anticorps anti-cxcr5 humanisés
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2018185050A1 (fr) 2017-04-03 2018-10-11 Covagen Ag Molécules de liaison à fgfr3
US11351267B2 (en) 2017-04-03 2022-06-07 Cilag Gmbh International FGFR3 binding molecules
WO2019207159A1 (fr) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Anticorps dirigé contre un peptide neurotoxique dérivé de tau et ses utilisations
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
WO2020053808A1 (fr) 2018-09-12 2020-03-19 Georg Dewald Procédé de diagnostic de troubles vasorégulateurs
WO2020099235A1 (fr) 2018-11-12 2020-05-22 Mediapharma S.R.L. Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3
WO2020157122A1 (fr) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Traitement de l'agent causal de l'angiogenèse
WO2020167912A1 (fr) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anticorps de type adressine anti-ganglions lymphatiques périphériques et leurs utilisations
WO2020242989A1 (fr) 2019-05-24 2020-12-03 Sanofi Méthodes de traitement de la sclérodermie généralisée
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
WO2021140173A1 (fr) 2020-01-10 2021-07-15 Biouniversa S.R.L. Méthodes et utilisations pour le traitement de tumeurs fibreuses solides avec des inhibiteurs de bags
WO2021183207A1 (fr) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions et procédés pour l'immunothérapie du cancer positif à npm1c
WO2022189632A1 (fr) 2021-03-12 2022-09-15 Fibrosys S.R.L. Anticorps monoclonaux pour le traitement d'infections virales

Also Published As

Publication number Publication date
AU631545B2 (en) 1992-12-03
FI895955A0 (fi) 1989-12-13
EP0362371A4 (en) 1990-10-24
KR900700134A (ko) 1990-08-11
AU3544589A (en) 1989-11-03
EP0362371A1 (fr) 1990-04-11
JPH02503867A (ja) 1990-11-15

Similar Documents

Publication Publication Date Title
AU631545B2 (en) Il-2 receptor-specific chimeric antibodies
CA2006865C (fr) Immunoglobulines humaines specifiques des recepteurs il-2
EP0566647B1 (fr) Immunoglobulines humanisees ameliorees
US5714350A (en) Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5882644A (en) Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
NZ227968A (en) Hybrid antibody and compositions
IL141158A (en) Human immunoglobulin that binds to the human willybrand factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 895955

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1989905832

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989905832

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989905832

Country of ref document: EP